TCM
ABUS icon

Traynor Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Traynor Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,000
Closed -$42K – 206
2021
Q4 		$42K Buy
+11,000
New +$42.7K 0.01% 213

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Traynor Capital Management's ABUS Position: Q1 2022 in Review

Traynor Capital Management sold out of Arbutus Biopharma (ABUS) in Q1 2022, closing a stake of 11,000 shares — an estimated $42K sold.

Traynor Capital Management first reported a position in ABUS in Q4 2021 and held it in 1 quarter. The position peaked at $42K in Q4 2021. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2022.

  • Traynor Capital Management reported no remaining Arbutus Biopharma position as of Q1 2022 after selling out during the quarter.
  • Traynor Capital Management sold 11,000 Arbutus Biopharma shares in Q1 2022, an estimated $42K.
  • Traynor Capital Management first reported a position in Arbutus Biopharma in Q4 2021 and held it in 1 quarter.
  • Traynor Capital Management's Arbutus Biopharma position peaked at $42K in Q4 2021.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2022.

Based on Traynor Capital Management's 13F filing for Q1 2022, filed 13 Apr 2022.